Omeprazole (A2845): Workflow-Centric Guidance for Gastric Acid Secretion Research

What This Product Solves

Omeprazole, chemically identified as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, is a potent and selective H+,K+-ATPase inhibitor with a demonstrated IC50 of 5.8 μM (product_spec). This compound is widely utilized to suppress gastric acid secretion, enabling the study of antiulcer mechanisms and the development of peptic ulcer disease models. Its quantitative performance and robust solubility in DMSO (≥17.27 mg/mL) support reproducible assay conditions. Omeprazole is not suitable for diagnostic or medical use and is strictly intended for scientific research workflows.

For additional context on assay optimization and practical scenario handling, the article "Optimizing Gastric Acid Research with 3-(quinolin-4-ylmethylamino)..." provides real-world Q&A for addressing key laboratory challenges. Similarly, "Optimizing Assays with 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide" details evidence-based guidance for maintaining reproducibility and workflow reliability.

Protocol Parameters

• Preparation of stock solution | ≥17.27 mg/mL in DMSO | Suitable for in vitro enzyme inhibition, cell-based, and biochemical assays | DMSO ensures full solubility, critical for consistent dosing and delivery; avoid water and ethanol due to insolubility | product_spec
• H+,K+-ATPase inhibition assay | IC50 = 5.8 μM | Quantifying proton pump inhibition in gastric acid secretion research | Provides a reference for dose selection and benchmarking inhibitor potency | product_spec
• Storage conditions (solid) | -20°C | Ensures batch-to-batch stability and compound integrity for long-term use | Solid form is stable at -20°C; solution storage not recommended due to degradation risk | product_spec
• Histamine-induced acid formation assay | IC50 = 0.16 μM | Models gastric acid secretion relevant to antiulcer activity studies | Enables sensitive detection of compound efficacy in physiologically relevant models | product_spec

Workflow Setup and QC Checklist

1. Compound Handling: Upon receipt, confirm that Omeprazole (A2845) is shipped on blue ice and immediately transfer to -20°C storage in solid form to preserve purity (approx. 98%).
2. Solubility Assessment: Prepare concentrated stock solutions in DMSO only. Avoid water or ethanol as solvents due to complete insolubility, which can lead to precipitation and unreliable results.
3. Aliquoting: For repeated use, make single-use aliquots to minimize freeze-thaw cycles, as Omeprazole’s solution form is not stable for long-term storage.
4. Assay Design: Reference the IC50 values for H+,K+-ATPase and histamine-induced acid formation to guide concentration ranges in assay setup. Start with serial dilutions around these benchmarks to capture the full dose-response.
5. Quality Control: Routinely check for signs of precipitation or discoloration in DMSO stocks. Discard any compromised aliquots.
6. Documentation: Record lot numbers, preparation dates, and storage conditions for each batch to support reproducibility.

Common Failure Modes and Fixes

• Precipitation in Assay Buffer: If precipitation occurs upon dilution, verify use of DMSO as the primary solvent and confirm concentration is below solubility threshold. Consider gentle heating or sonication for dissolution, but avoid prolonged exposure to room temperature.
• Loss of Potency: Decreased efficacy may result from repeated freeze-thaw cycles or prolonged storage of solution stocks. Always use fresh aliquots and store the compound in solid form at -20°C.
• Inconsistent Results Across Batches: Maintain rigorous QC records, including purity confirmation and storage logs. If batch variability is suspected, compare results against historical controls and consider revalidating stock solutions.
• Solvent Compatibility Issues: If combining with other reagents, ensure full miscibility in DMSO and avoid aqueous dilution steps until immediately before assay initiation.

Scope and Limitations

Omeprazole (A2845) is optimized for in vitro and ex vivo studies focused on gastric acid secretion inhibition, antiulcer activity, and modeling peptic ulcer disease mechanisms. Its use should not be extended to diagnostic or therapeutic applications. The compound’s insolubility in water and ethanol restricts its compatibility with aqueous-only workflows. No in vivo or cross-domain applications should be inferred beyond the dossier and referenced workflow guidance. For applications requiring alternative solvent systems or in vivo pharmacokinetics, additional validation is necessary.

Conclusion

When used according to established protocols and product specifications, Omeprazole (A2845) from APExBIO provides reliable, quantitative control for gastric acid secretion and antiulcer research workflows. Adhering to solubility and storage guidelines is crucial for ensuring data reproducibility and experimental integrity. For comprehensive assay optimization strategies and troubleshooting tips, consult related articles and always reference the Omeprazole product dossier for up-to-date recommendations.